hrvatski

Azitromicin se sa sigurnošću može primjenjivati uz ciklosporin u liječenju infekcija dišnog sustava u bolesnika s transplatiranim bubregom

A study was designed to examine the safety of azithromycin for the treatment of respiratoty tract infections in patients concomitantly receiving cyclosporin therapy The study included 64 renal transplant patients (43 males and 21 females, age 12-70 years; mean age 43,26 years) suffering from upper (bacterial pharyngitisltonsilitis, otitis media, sinusitis) and lower respiratory tract infections (acute bacterial bronchitis, exacerbation of chronic bronchitis), treated at the Zagreb University Hospital, Croatia, between September 1995 and February 1999. Azithromycin was administered orally over 5 days (500 mg once daily on day 1, followed by 250 mg on days 2-5), at least one hour before or two hours after meals. Cyclosporin blood levels were determined and laboratory safety tests (hematology and biochemist,y) were performed at baseline, and on days 7 and 14. There was no significant difference in the blood cyclosporin levels before (mean 115,16 nglmL; SD 42,5 7), 7 days (mean 124,86 nglmL; SD 48,56) and 14 days (mean 1 09,66 ng/mL; SD 38,03) after azithromycin therapy Renal function remained unchanged (creatinine values showed no significant change). Both the tolerability of azithromycin and clinical response to therapy were very good. Our study demonstrated that azithromycin therapy has no significant effect on blood cyclosporin levels. Therefore, azithromycin can safely be used in renal transplant patients without the need of exceptional monitoring of cyclosporin blood levels. This, combined with its high efficacy, good tolerability and simple dosage, makes azithromycin a promising agent in the treatment of upper and lower respiratory tract infections in renal transplant patients.

azitromicin; ciklosporin; interakcija; transplatacija bubrega

nije evidentirano